Sanofi Stock Forecast for 2023 - 2025 - 2030
Updated on 05/19/2024
Sanofi Stock Forecast and Price Target
If the average 2024 price target of 109.50€ recently set by nine prominent experts for Sanofi is met, there would be a potential upside of approximately 22.8% from the last closing price in May, 2024. The high estimate is 125.00€, and the low is 80.00€. Even if you are not interested in SAN stock, you should be aware of its competitors and their current standings.
22.80% Upside
Sanofi Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Sanofi's Price has decreased from 74.89€ to 0.00€ – a 100.00% drop. For next year, the 21 analysts predict Fair Value of 103.77€, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is Fair Valueof 156.68€, which would mean a seven-year growth forecast of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$770.00 | Buy/Sell | $636.99 | 13.96% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$166.42 | Buy/Sell | $178.42 | 9.66% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£121.10 | Buy/Sell | £165.99 | 34.64% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$104.09 | Buy/Sell | $118.92 | 21.53% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$312.47 | Buy/Sell | $303.65 | 2.41% |
Sanofi Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Sanofi's Revenue has grown, increasing from 37.37€B to 46.03€B – an increase of 23.18%. For next year, the 13 analysts predict Revenue of 46.96€B, which would mean an increase of 2.01%. Over the next seven years, the pros' prediction is Revenueof 59.81€B, which would mean a seven-year growth forecast of 29.93%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CSL Stock Forecast | CSL | Outperform |
12
|
$280.00 | Buy/Sell | $205.51 | -26.66% |
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$44.03 | Buy/Sell | $58.15 | 22.64% |
| CL Stock Forecast | Colgate-Palmolive Co | Outperform |
18
|
$94.13 | Buy/Sell | $88.97 | 4.64% |
.jpg)
Sanofi Dividend per Share Forecast for 2023 - 2025 - 2030
Sanofi's Dividend per Share has increased by 17.50% In the last three years, going from 3.20€ to 3.76€. In the next year, analysts expect Dividend per Share to reach 3.78€ – an increase of 0.53%. For the next seven years, the forecast is for Dividend per Share to grow by 24.47%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥5.53k | Buy/Sell | ¥5.24k | 7.58% |
| 4519 Stock Forecast | Chugai Pharmaceutical | Outperform |
6
|
¥5.01k | Buy/Sell | ¥4.92k | 21.83% |
| BAS Stock Forecast | BASF | Outperform |
12
|
48.88€ | Buy/Sell | 49.50€ | 14.57% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALC Stock Forecast | Alcon | Outperform |
8
|
CHF80.08 | Buy/Sell | CHF90.64 | 20.97% |
| CTVA Stock Forecast | Corteva | Outperform |
12
|
$56.45 | Buy/Sell | $61.72 | 15.15% |
| BEI Stock Forecast | Beiersdorf | Outperform |
17
|
144.70€ | Buy/Sell | 137.41€ | 2.97% |
Sanofi EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Sanofi's EBITDA has grown by 19.55%, from 10.47€B to 12.52€B. For the next year, analysts are expecting EBITDA to reach 14.31€B – an increase of 14.29%. Over the next seven years, experts predict that EBITDA will grow by 40.94%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$230.57 | Buy/Sell | $299.62 | 25.12% |
| BAYN Stock Forecast | Bayer | Hold |
5
|
28.58€ | Buy/Sell | 45.15€ | 4.97% |
| COLO B Stock Forecast | Coloplast A/S | Hold |
18
|
kr850.00 | Buy/Sell | kr812.28 | 5.88% |
Sanofi EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Sanofi's EBIT has grown from 7.59€B to 9.20€B – a 21.30% increase. Next year, analysts are expecting EBIT to reach 12.95€B – an increase of 40.75%. Over the next seven years, the forecast is for EBIT to grow by 112.09%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CHD Stock Forecast | Church & Dwight Co Inc | Hold |
11
|
$106.39 | Buy/Sell | $96.90 | 1.51% |
| ARGX Stock Forecast | argenx | Outperform |
4
|
339.90€ | Buy/Sell | 531.81€ | 28.39% |
| BNTX Stock Forecast | BioNTech | Outperform |
12
|
$90.61 | Buy/Sell | $123.75 | 3.24% |
Sanofi EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Sanofi's EPS has decreased from 5.86€ to 0.00€ – a 100.00% drop. For next year, the 21 analysts predict EPS of 8.12€, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is EPSof 12.26€, which would mean a seven-year growth forecast of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$149.40 | Buy/Sell | $245.24 | 45.58% |
| BGNE Stock Forecast | BeiGene | Buy |
6
|
$172.85 | Buy/Sell | $285.19 | 55.63% |
| BAX Stock Forecast | Baxter International Inc | Hold |
17
|
$35.25 | Buy/Sell | $44.86 | 24.82% |
.jpg)